Monitoring immune responses in cancer patients receiving tumor vaccines

被引:26
作者
Walker, EB
Disis, MLN
机构
[1] Robert W Franz Canc Res Ctr, Earle A Chiles Res Inst, Providence Portland Med Ctr, Portland, OR 97213 USA
[2] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA
关键词
immunomonitoring assays; cancer vaccines;
D O I
10.1080/08830180305226
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Clinical evaluation of therapeutic tumor vaccines has resulted in examination and comparison of the types of immune function assays required to monitor tumor antigen-stimulated T cell effector function in immunized patients. Three of the most commonly used assays include ELISPOT, tetramer assay, and cytokine flow cytometry (CFC). Discussed are the method and principles for each assay and an assessment of important methodological, reagent, and data acquisition issues that are relevant for the accurate and effective use of the assays. The sensitivity and utility of the assays and present arguments advocating their integrated use in future immunomonitoring studies are also discussed.
引用
收藏
页码:283 / 319
页数:37
相关论文
共 140 条
[41]   Detection and quantification of blood-derived CD8(+) T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens [J].
Herr, W ;
Schneider, J ;
Lohse, AW ;
zumBuschenfelde, KHM ;
Wolfel, T .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 191 (02) :131-142
[42]   A T cell clone's avidity is a function of its activation state [J].
Hesse, MD ;
Karulin, AY ;
Boehm, BO ;
Lehmann, PV ;
Tary-Lehmann, M .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1353-1361
[43]  
Hoffmann TK, 2000, CYTOMETRY, V41, P321, DOI 10.1002/1097-0320(20001201)41:4<321::AID-CYTO11>3.3.CO
[44]  
2-0
[45]   Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule [J].
Hörig, H ;
Lee, DS ;
Conkright, W ;
Divito, J ;
Hasson, H ;
LaMare, M ;
Rivera, A ;
Park, D ;
Tine, J ;
Guito, K ;
Tsang, KWY ;
Schlom, J ;
Kaufman, HL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (09) :504-514
[46]   A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection [J].
Jonuleit, H ;
Giesecke-Tuettenberg, A ;
Tüting, T ;
Thurner-Schuler, B ;
Stuge, TB ;
Paragnik, L ;
Kandemir, A ;
Lee, PP ;
Schuler, G ;
Knop, J ;
Enk, AH .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) :243-251
[47]   Dendritic cells as a tool to induce anergic and regulatory T cells [J].
Jonuleit, H ;
Schmitt, E ;
Steinbrink, K ;
Enk, AH .
TRENDS IN IMMUNOLOGY, 2001, 22 (07) :394-400
[48]   Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy [J].
Kalams, SA ;
Goulder, PJ ;
Shea, AK ;
Jones, NG ;
Trocha, AK ;
Ogg, GS ;
Walker, BD .
JOURNAL OF VIROLOGY, 1999, 73 (08) :6721-6728
[49]  
Karanikas V, 2000, CLIN CANCER RES, V6, P829
[50]   Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy [J].
Keilholz, U ;
Weber, J ;
Finke, JH ;
Gabrilovich, DI ;
Kast, WM ;
Disis, ML ;
Kirkwood, JM ;
Scheibenbogen, C ;
Schlom, J ;
Maino, VC ;
Lyerly, HK ;
Lee, PP ;
Storkus, W ;
Marincola, F ;
Worobec, A ;
Atkins, MB .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (02) :97-138